Literature DB >> 17420712

Nuclear medicine applications in molecular imaging: 2007 update.

F G Blankenberg1, H W Strauss.   

Abstract

This review examines several classes of radiolabeled agents, including analogs localizing in somatostatin, benzodiazepine and dopamine receptors; analogs of progesterone and estrogen; and agents localizing in lesions with hypoxia. It concludes the status of agents advocated for detecting angiogenesis and inflammation. The current clinical status of these agents, and their potential roles in diagnosis and treatment are discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17420712

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  5 in total

1.  Molecular imaging by micro-CT: specific E-selectin imaging.

Authors:  Caroline Wyss; Stephan C Schaefer; Lucienne Juillerat-Jeanneret; Lucienne Lagopoulos; Hans-Anton Lehr; Christoph D Becker; Xavier Montet
Journal:  Eur Radiol       Date:  2009-05-14       Impact factor: 5.315

2.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

Review 3.  Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview.

Authors:  L M Riou; A Broisat; J Dimastromatteo; G Pons; D Fagret; C Ghezzi
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 4.  Role of Nuclear Imaging to Understand the Neural Substrates of Brain Disorders in Laboratory Animals: Current Status and Future Prospects.

Authors:  Annunziata D'Elia; Sara Schiavi; Andrea Soluri; Roberto Massari; Alessandro Soluri; Viviana Trezza
Journal:  Front Behav Neurosci       Date:  2020-12-11       Impact factor: 3.558

5.  Detection of vulnerable atherosclerotic plaque and prediction of thrombosis events in a rabbit model using 18F-FDG -PET/CT.

Authors:  Quan-ming Zhao; Xin Zhao; Ting-ting Feng; Ming-duo Zhang; Xu-cui Zhuang; Xue-cheng Zhao; Li-qin Li; De-peng Li; Yu Liu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.